Tata Consultancy Services is currently trading at Rs. 2083.60, up by 26.90 points or 1.31% from its previous closing of Rs. 2056.70 on the BSE.
The scrip opened at Rs. 2060.10 and has touched a high and low of Rs. 2088.00 and Rs. 2060.10 respectively. So far 39967 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 2296.00 on 03-Sep-2019 and a 52 week low of Rs. 1784.00 on 29-Oct-2018.
Last one week high and low of the scrip stood at Rs. 2106.95 and Rs. 1975.00 respectively. The current market cap of the company is Rs. 780777.45 crore.
The promoters holding in the company stood at 72.05%, while Institutions and Non-Institutions held 23.81% and 4.15% respectively.
Tata Consultancy Services’ (TCS) Connected Clinical Trials (CCT) platform has won the 2019 European Innovations Award at the Summit for Clinical Operations Executives (SCOPE) – Europe.
Clinical Research News’ European lnnovations Awards recognize outstanding examples of applied strategic innovation – partnerships, deployments, and collaborations that manifestly improve the clinical trial process. CCT was recognized for its thoughtful approach to solving tough industry problems, its ability to provide quantifiable returns on investment and ease of deployment.
Tata Consultancy Services is an IT services, consulting and business solutions provider that has been partnering with the world’s largest businesses in their transformation journeys for the last fifty years.